Tengsheng Biopharmaceuticals announced that the National Health Commission has included the combination therapy of ambavirumab/romisevirumab in the "New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Version 9)"

Ambavirumab/romisevirumab combination therapy is my country's first self-developed anti-new coronavirus drug that has been proven effective in an international multi-center large-sample randomized, double-blind, placebo-controlled study

The test data of in vitro chimeric virus experiments show that the combination therapy of ambavirumab/romisevirumab maintains neutralizing activity on the main variants of the new coronavirus that have received widespread attention, such as Omicron, Delta, and Delta+.

BEIJING AND DURHAM, N.

Luo Yongqing, President and General Manager of Greater China of Tengsheng Biopharmaceuticals, said: "The inclusion of Tengsheng Biopharmaceutical's combination therapy in the latest version of the new coronavirus diagnosis and treatment plan reflects the recognition of this new coronavirus treatment plan by national health authorities and industry experts, and further confirms that The importance of our antibody combination therapy for China's new crown patients and epidemic prevention and control

Tengsheng Biopharma is actively promoting the production and supply process of the drug to bring the combination therapy of Ambavirumab/Romisevirumab to patients in need as soon as possible

Ambavirumab/romisevirumab combination therapy (previously known as BRII-196/BRII-198 combination therapy) was approved by the National Medical Products Administration (NMPA) on December 8, 2021 for the treatment of mild Adult and adolescent (12-17 years old, weight ≥40 kg) patients with novel coronavirus infection (COVID-19) with common type and high risk factors for progression to severe disease (including hospitalization or death)

The marketing approval of ambivirumab/romisevirumab by the China National Medical Products Administration is based on the final phase 3 clinical trial of the ACTIV-2 study including 837 enrolled outpatients supported by the National Institutes of Health (NIH) result

The test data of in vitro chimeric virus experiments show that the combination therapy of ambavirumab/romisevirumab is effective against the newly discovered new coronavirus variant B.

About Ambavirumab/Romisevirumab Combination Therapy (formerly BRII-196/BRII-198)

Ambavirumab and romisevirumab are non-competitive novel severe acute respiratory infections obtained by Tengsheng Biopharmaceuticals in cooperation with Shenzhen Third People's Hospital and Tsinghua University from patients with novel coronavirus pneumonia (COVID-19) during the recovery period.

In October 2021, Tengsheng Biopharma initiated the submission of an Emergency Use Authorization (EUA) application to the U.

In response to the new crown epidemic caused by the "Delta" variant strain in China, Tengsheng Biopharmaceutical donated nearly 3,000 copies of Amba through cooperation with Chinese government departments and hospitals from June to December 2021.

About the "New Coronavirus Pneumonia Diagnosis and Treatment Program"

As a severe acute respiratory infectious disease, novel coronavirus pneumonia (COVID-19) has become a major public health emergency threatening the world

Source: Tengsheng Boyao Biotechnology Co.